Spots Global Cancer Trial Database for nmibc
Every month we try and update this database with for nmibc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | NCT01469221 | Bladder Cancer | Apaziquone Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | NCT01469221 | Bladder Cancer | Apaziquone Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT | NCT04839029 | Bladder Cancer Bladder Neoplas... | Bipolar En bloc... Monopolar En bl... | 18 Years - | Benha University | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder | NCT03519256 | Urinary Bladder... | Nivolumab BCG BMS-986205 | 18 Years - | Bristol-Myers Squibb | |
| Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | NCT01410565 | Bladder Cancer | Apaziquone Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer | NCT06310369 | Bladder Cancer | radiation thera... | 18 Years - 100 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | NCT05136898 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | NCT01475266 | Bladder Cancer | EO9 (Apaziquone... Placebo | 20 Years - | Nippon Kayaku Co., Ltd. | |
| Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer | NCT02075060 | Non Muscle-inva... | IPOI (pre-opera... IPOP (post-oper... | 18 Years - | Poitiers University Hospital | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | NCT01410565 | Bladder Cancer | Apaziquone Placebo | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | NCT03022825 | Bladder Cancer | N-803 and BCG N-803 | 18 Years - | ImmunityBio, Inc. | |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT03558503 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | NCT03914794 | Bladder Cancer NMIBC Non-Muscle Inva... Urothelial Carc... | Pemigatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI® | NCT03191578 | High-Risk Non-M... | RUTI® Placebo | 18 Years - 99 Years | Archivel Farma S.L. | |
| A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer | NCT04688931 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 TURBT | 18 Years - | UroGen Pharma Ltd. | |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | NCT04917809 | Bladder Cancer Recurrent Bladd... FGFR3 Gene Muta... | Erdafitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT03558503 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| Retrospective Chart Review of Valstar | NCT01304173 | Carcinoma in Si... | 18 Years - | Endo Pharmaceuticals | ||
| The Bladder Instillation Comparison Study | NCT02695771 | Urinary Bladder... | Mitomycin C Gemcitabine | 18 Years - | Spectrum Health Hospitals | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting | NCT02560584 | Bladder Cancer | Hexaminolevulin... KARL STORZ D-Li... | 18 Years - | Photocure | |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | NCT06331299 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-103 | 18 Years - | UroGen Pharma Ltd. | |
| Blue Light Cystoscopy With Cysview® Registry | NCT02660645 | Bladder Cancer | Hexaminolevulin... Karl Storz D-Li... | 18 Years - | Photocure | |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | NCT03528694 | Non-muscle-inva... | Durvalumab (MED... Bacillus Calmet... | 18 Years - 130 Years | AstraZeneca | |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05375903 | Non-muscle Inva... NMIBC Carcinoma in Si... Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-301 UGN-201 Gemcitabine | 18 Years - | UroGen Pharma Ltd. | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | NCT03636256 | Bladder Cancer Urothelial Carc... Urinary Bladder... Urinary Bladder... Urogenital Neop... Urologic Neopla... Urologic Cancer Malignant Tumor... Cancer of the B... | NanoDoce (direc... NanoDoce (intra... Institutional S... NanoDoce (intra... | 18 Years - | NanOlogy, LLC | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT | NCT04839029 | Bladder Cancer Bladder Neoplas... | Bipolar En bloc... Monopolar En bl... | 18 Years - | Benha University | |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | NCT05243550 | Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-102 | 18 Years - | UroGen Pharma Ltd. | |
| The Bladder Instillation Comparison Study | NCT02695771 | Urinary Bladder... | Mitomycin C Gemcitabine | 18 Years - | Spectrum Health Hospitals | |
| Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | NCT05975151 | Bladder Cancer | Pseudomonas aer... | 18 Years - 90 Years | Qilu Hospital of Shandong University | |
| Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | NCT01475266 | Bladder Cancer | EO9 (Apaziquone... Placebo | 20 Years - | Nippon Kayaku Co., Ltd. | |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | NCT02307487 | Bladder Cancer Neoplasms Urinary Bladder... Urologic Diseas... | 120 mg MMC in 9... 140 mg MMC in 9... 160 mg MMC in 9... 120 mg MMC in 6... 140 mg MMC in 6... 160 mg MMC in 6... | 18 Years - | UroGen Pharma Ltd. | |
| CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | NCT04811846 | Urinary Bladder... Transitional Ce... Urogenital Neop... Circulating Tum... Neoplasms | Bipolar transur... Bipolar transur... | 18 Years - | University Teaching Hospital Hall in Tirol | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | NCT02891460 | Urinary Bladder... Urologic Neopla... Neoplasms Urinary Bladder... Urologic Diseas... | 40 mg MMC in 40... 80 mg MMC in 40... | 18 Years - | UroGen Pharma Ltd. | |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | NCT05483868 | Non-muscle-inva... Muscle-Invasive... | AU-011 AU-011 in Combi... AU-011 in Combi... | 18 Years - | Aura Biosciences | |
| A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer | NCT06181266 | NMIBC High Risk NMIBC Non Muscle Inva... | ZH9 | 18 Years - 99 Years | Prokarium Ltd | |
| Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test | NCT05176145 | Non-muscle Inva... | VisioCyt® | 18 Years - | Vitadx | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer | NCT04386746 | Urothelial Carc... Bladder Cancer | Gemcitabine Docetaxel | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05375903 | Non-muscle Inva... NMIBC Carcinoma in Si... Bladder Cancer Urothelial Carc... Urothelial Carc... | UGN-301 UGN-201 Gemcitabine | 18 Years - | UroGen Pharma Ltd. | |
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | NCT02852564 | Bladder Cancer | Ethacrynic Acid | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
